Editing Nanomedicine, Targeted Delivery, and Molecular Therapeutics (section)

== <span style="color: #FFFFFF;">Understanding</span> ==
Nanomedicine is understood through '''precision''' and '''delivery'''.

'''The mRNA-LNP Success Story''': The Moderna and BioNTech COVID vaccines encapsulate mRNA in lipid nanoparticles — protecting the fragile mRNA from degradation and enabling cellular uptake. This was not invented for COVID: decades of work by Katalin Karikó, Drew Weissman, Pieter Cullis, and others developed both the modified nucleoside chemistry (Nobel 2023, Karikó and Weissman) and the LNP formulation technology. COVID was the first mass deployment. The same platform now enables cancer vaccines, HIV vaccines, and in vivo protein replacement therapy. The LNP is one of the most consequential nanomedicine achievements in history.

'''The EPR Effect's Limitations''': The EPR effect — passive accumulation of nanoparticles in tumors — is the theoretical basis of most cancer nanomedicine. But a landmark 2016 meta-analysis found that only 0.7% of administered nanoparticle dose actually reaches solid tumor tissue in animal models. Human data is even less encouraging. The EPR effect is heterogeneous, patient-specific, and tumor-type dependent. This has forced a rethinking of passive targeting strategies and a shift toward active targeting and combination approaches.
</div>

<div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">